Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
November 2015, Vol 6, No 10
November 2015, Vol 6, No 10
Screening in Younger First-Degree Relatives of Patients with CRC
By
Rosemary Frei, MSc
Cancer Screening
,
Personalized Medicine
November 2015, Vol 6, No 10
A study from the Centers for Disease Control and Prevention documented an average 38% colorectal cancer (CRC) screening rate among people aged 40 to 49 years, and a 69.7% rate in those aged ?50 years with a first-degree relative with CRC. An earlier analysis of National Health Interview Survey (NHIS) data from 2005 and 2010 showed that first-degree relatives of patients with CRC were 70% more likely to have a colonoscopy than their counterparts.
Read Article
MRI Screening of Women at Average Risk for Breast Cancer Improves Detection
By
Corbin Davis
Breast Cancer
,
Cancer Screening
,
Personalized Medicine
November 2015, Vol 6, No 10
San Francisco, CA—Magnetic resonance imaging (MRI) screening of women who are at average risk for breast cancer had a mean additional cancer diagnosis yield of 15.8 per 1000 patients, surpassing the yields for digital breast tomosynthesis and ultrasound in a new study. The results were presented at the 2015 Breast Cancer Symposium, by Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH Aachen University, Germany. This suggests that breast MRI screening alone every 3 years may be sufficient for women at average risk.
Read Article
Significant Benefits Seen with 2 New Options for Patients with Renal-Cell Carcinoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
Vienna, Austria—Patients with advanced, pretreated renal-cell carcinoma (RCC) who have limited treatment options got good news from 2 important practice-changing trials, CheckMate 025 and METEOR, which were presented as late-breaking abstracts at the 2015 European Cancer Congress (ECC). CheckMate 025 showed a survival benefit for nivolumab (Opdivo) over standard therapy with everolimus (Afinitor) in patients with previously treated advanced RCC. This is the first trial to show a survival benefit for an immune checkpoint inhibitor after standard therapy has failed. METEOR showed that cabozantinib (Cometriq) nearly doubled progression-free survival (PFS) compared with standard everolimus in patients with advanced RCC whose disease progressed with previous vascular endothelial growth factor (VEGF) receptor (VEGFR)-targeted therapy.
Read Article
The NCCN New Tool to Assess Value Discourages Patients’ Hope
By
Robert Goldberg, PhD
Value-Based Care
,
VBCC Perspectives
November 2015, Vol 6, No 10
In October, the National Comprehensive Cancer Network (NCCN) released its first set of “flash cards” or “Evidence Blocks” as a tool for evaluating treatment decisions, seeking to solve a drug cost problem that does not exist, by adding to a problem that does: insurers shifting the cost of cancer treatment to patients. In so doing, the NCCN could inadvertently increase the rate at which patients with cancer choose assisted suicide.
Read Article
FDA News - November 2015
FDA Approvals, News & Updates
November 2015, Vol 6, No 10
Read Article
Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy
By
Wayne Kuznar
November 2015, Vol 6, No 10
To take full benefit of advances made possible by Next-Generation Sequencing, more American patients with cancer must be involved in clinical trials, said Raju Kucherlapati, PhD, Professor of Genetics, Harvard Medical School, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
New Guidelines for Breast Cancer Screening Still Not a Definitive Answer for Women Aged >40 Years
By
Kristen Chanley
Clinical Guidelines
,
Policies & Guidelines
November 2015, Vol 6, No 10
“Especially for average-risk women, decisions to undergo regular mammography screening must also consider the harms of mammography,” stated Nancy L. Keating, MD, MPH, and Lydia E. Pace, MD, MPH.
Read Article
Everolimus, 177Lu-DOTATATE Potentially 2 Practice-Changing Options in NETs
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
“Everolimus is the first targeted agent to show robust antitumor activity with acceptable tolerability across a broad spectrum of NETs,” said James C. Yao, MD.
Read Article
NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies
By
Wayne Kuznar
Clinical Guidelines
,
NCCN Conference Highlights
,
Policies & Guidelines
November 2015, Vol 6, No 10
The National Comprehensive Cancer Network (NCCN) has added a new value criterion to its clinical practice guidelines in the form of “Evidence Blocks” for the evaluation of treatment options.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma